Home » Clinical » Agenus reports net reduction attributable to common stockholders of $5.

Agenus reports net reduction attributable to common stockholders of $5.

Saponin Platform: QS-21 Stimulon Adjuvant QS-21 Stimulon adjuvant is among the most broadly tested vaccine adjuvants in clinical development. QS-21Stimulon is designed to strengthen the body's immune response to a vaccine's antigen, rendering it more effective thus. QS-21 Stimulon is an essential component of 21 investigational vaccines for infectious diseases, cancers and degenerative disorders. Licensees include GSK and Janssen Alzheimer Immunotherapy. Agenus is normally entitled to receive milestone payments in addition to royalties for a decade after commercial launch..Transplant candidates should undergo careful screening for pores and skin cancers before a transplant is received by them, the researchers said. It is possible that some melanomas may be present at the time of transplant and commence to spread aggressively when patients start taking immunosuppressive medications, Robbins noted. Close monitoring for melanoma following a transplant can be important so that the disease can be caught at a youthful, even more treatable stage, she added.

3M and MicroDose Technologies Inc.